Friday, Apr 23 2021 | Time 15:02 Hrs(IST)
image
  • Twenty-five "sickest patients" died in last 24 hrs at Sir Ganga Ram hospital in Delhi
  • DRDO's Dhanvantri Covid Hospital at Ahmedabad to get functional from Saturday
  • IPL 2021: Axar Patel recovers from COVID-19, joins DC squad
  • IPL 2021: Axar Patel recovers from COVID-19, joins DC squad
  • IPL 2021: Axar Patel recovers from COVID-19, joins DC squad
  • COVID: 110 test positive in Arunachal, tally mounts to 17, 296
  • ECoR dispatches first Oxygen train to Maharastra, Four oxygen tankers leave for Visakhapatnam, Pune
  • At least nine drown in river Ganges in Patna
  • Two killed in light aircraft crash in Russia's Irkutsk region - Emergencies
  • J&K Bank heist: Vehicle used by robbers, snatched rifle recovered in Baramulla
  • India, US will act in concert to mobilise climate finance, deploy clean energy
  • Traffic remains suspended to dozens of far-flung, remote areas in Kashmir
  • TDP senior leader Dhulipalla Narendra arrested
  • CAR hopes to secure loans from Russia, can offer mining guarantees: Minister
  • Six die while swimming in two separate accidents
Business Economy


Zydus to present new scientific data on Lipaglyn in the US

New Delhi, Jun 8 (UNI) Healthcare services provider, Zydus Cadila today said the new scientific and clinical data on Lipaglyn (Saroglitazar) will be presented at the 75th annual scientific sessions of the American Diabetes Association (ADA) in Boston, Massachusetts, US from 5th to 9th June,2015. Several analyses of real-world patient data of Lipaglyn (Saroglitazar) will also be presented, the company said in a BSE filing. ''This new robust scientific data on the safety and efficacy of Lipaglyn (Saroglitazar) reflects our continued commitment to millions of patients living with Diabetes, Dyslipidemia and non-alcoholic fatty liver disease,'' Chairman and MD, Zydus Cadila, Pankaj R Patel said. Lipaglyn (Saroglitazar) was launched in September 2013 in India, for treating Diabetic Dyslipidemia in patients with type two Diabetes not controlled by statins. UNI PY SY 1151
More News

23 Apr 2021 | 2:43 PM

Kozhikode, Apr 23 (UNI) Following were the rates in the Kozhikode Oil market today per quintal,
Copra Office Rs 13,200,
Dilpas Rs 13,300,
Rajapur Rs 18,700,
Bolls Rs 17,100,
Coconut oil Rs 20,750.

see more..

23 Apr 2021 | 2:42 PM

Kozhikode, Apr 23 (UNI) Following were the rates in the Kozhikode Spices market today per quintal,
Pepper Nadan, Rs 36,000,
Chettan Rs 37,800,
Wynadan Rs 39,000,
Ginger (new) Rs 16,000
Cardamom Green (New) Rs 3,550.

see more..

23 Apr 2021 | 2:41 PM

Kozhikode, Apr 23 (UNI) Following was the rate in the Kozhikode Rubber market today,
RMA LOT (RSS 4) Rs 15,800
(RSS 5) Rs 14,500.

see more..

Paritosh Jauhari Joins Successive Technologies as Chief Technology Officer

23 Apr 2021 | 1:52 PM

NOIDA, India, April 23, 2021 /PRNewswire/ - Successive Technologies, a next-gen (CMMI Level-3) technology consulting and services company headquartered in India, is proud to further strengthen its leadership team with the appointment of Paritosh Jauhari, as the Chief Technology Officer.

see more..
Zydus Cadila receives final approval from USFDA for Propafenone Hydrochloride Extended-Release Capsules

Zydus Cadila receives final approval from USFDA for Propafenone Hydrochloride Extended-Release Capsules

23 Apr 2021 | 1:12 PM

Mumbai, Apr 23 (UNI) Pharma major, Zydus Cadila has received final approval from the USFDA to market Propafenone Hydrochloride Extended Release Capsules USP, 225 mg, 325 mg, and 425 mg.

see more..
image